Evommune and Axcelead Drug Discovery Partners Launch A Collaboration On A PKCtheta Program To Kick-off Evommune’s Inflammation Pipeline

Los Altos, California, USA and Fujisawa, Kanagawa, Japan–Dec. 10, 2020 –Evommune, Inc., aprivate R&D company andinnovation engine...

Continue ReadingEvommune and Axcelead Drug Discovery Partners Launch A Collaboration On A PKCtheta Program To Kick-off Evommune’s Inflammation Pipeline

MAPLIGHT THERAPEUTICS ANNOUNCES COMPLETION OF DOSING IN PHASE 1 STUDY OF THERAPY FOR SOCIAL DEFICIT IN AUTISM SPECTRUM DISORDER

SAN FRANCISCO, November 23, 2020 – MapLight Therapeutics today announced it has completed dosing of healthy volunteers across five cohorts in a Phase 1...

Continue ReadingMAPLIGHT THERAPEUTICS ANNOUNCES COMPLETION OF DOSING IN PHASE 1 STUDY OF THERAPY FOR SOCIAL DEFICIT IN AUTISM SPECTRUM DISORDER